Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 8:31 PM ET

Date/Time Source News Release
06/10/2022 07:30 PM EDT ACCESSWIRE Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.
06/08/2022 04:05 PM EDT ACCESSWIRE Novamind Shareholders Approve Proposed Acquisition by Numinus
06/02/2022 08:00 AM EDT ACCESSWIRE Novamind Announces New Patient Financing Options
05/31/2022 08:00 AM EDT ACCESSWIRE Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
05/27/2022 08:00 AM EDT ACCESSWIRE Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders of Novamind Vote FOR the Proposed Plan of Arrangement
05/19/2022 08:00 AM EDT ACCESSWIRE Novamind Launches Group Psychedelic Treatment for Frontline Workers
05/11/2022 08:00 AM EDT ACCESSWIRE Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement
05/10/2022 08:00 AM EDT ACCESSWIRE Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
05/02/2022 08:00 AM EDT ACCESSWIRE Novamind Announces Virtual Group Health Coaching
04/12/2022 07:00 AM EDT PR Newswire Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Page

Additional News

As of June 4, 2025 • 8:31 PM ET

Date/Time Source News Release
08/04/2022 08:00 AM EDT Green Market Report DEA's Psychedelics 'To Do' List Is Growing
06/01/2022 01:25 PM EDT Green Market Report Novamind Reports Earnings Ahead of Acquisition
06/01/2022 08:17 AM EDT Green Market Report Big Pharma Begins To Take Psychedelics Seriously
05/31/2022 09:08 AM EDT SeekingAlpha Novamind GAAP EPS of -C$0.05, revenue of C$3.23M
04/13/2022 08:39 AM EDT Green Market Report Psychedelics Bump Up Against the Iffy World of Healthcare Insurance
03/09/2022 09:41 AM EST SeekingAlpha Novamind to conduct phase 2 trial of psilocybin for depression
03/02/2022 09:03 AM EST Green Market Report Novamind Delivers Rising Revenues
03/01/2022 09:19 AM EST SeekingAlpha Novamind GAAP EPS of -$0.08, revenue of $2.45M
02/03/2022 09:52 AM EST Green Market Report Novamind Chosen for End-of-Life Psychedelic Drug Study
12/23/2021 09:06 AM EST SeekingAlpha Novamind to acquire mental health practice Foundations for Change
Page
  • 1
  • 2

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.